Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03554174
PHASE1

Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

Sponsor: Yale University

View on ClinicalTrials.gov

Summary

The primary goal of this pilot study is to investigate whether psilocybin alters neuroplasticity in people with major depressive disorder. The primary hypothesis is that psilocybin will result in neuroplastic changes that parallel improvement in symptoms of depression.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2018-02-27

Completion Date

2026-09

Last Updated

2025-11-05

Healthy Volunteers

No

Interventions

DRUG

Low Dose Psilocybin

0.1 mg/kg psilocybin capsule

DRUG

Placebo

microcrystalline cellulose capsule

DRUG

Medium Dose Psilocybin

0.3 mg/kg psilocybin capsule

Locations (1)

VA Connecticut Healthcare System, West Haven Campus

West Haven, Connecticut, United States